SCHEMBL3483860

SCHEMBL3483860

O=C(C=Cc1ccccc1O)c1cccc(NS(=O)(=O)c2cccc(O)c2)c1

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.53
CHRNA7 P36544 4/20 0.52
PFKFB3 Q16875 1/20 0.48
ALPL P05186 1/20 0.47
ALPI P09923 1/20 0.47
ALPG P10696 1/20 0.47
NR1H4 Q96RI1 1/20 0.47
TYR P14679 1/20 0.47
PTPN1 P18031 1/20 0.47
HSD17B2 P37059 3/20 0.47
HSD17B1 P14061 2/20 0.47
KMT2A Q03164 1/20 0.46
HDAC2 Q92769 1/20 0.44
HDAC8 Q9BY41 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44
MAPT P10636 2/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3483857 1.00 PKM (0.53) PKMCHRNA7PFKFB3ALPLALPI
SCHEMBL3483869 0.92 PKM (0.52) PKMCHRNA7PFKFB3ALPLALPI
SCHEMBL3483872 0.92 PKM (0.52) PKMCHRNA7PFKFB3ALPLALPI
SCHEMBL3483624 0.91 PKM (0.53) PKMCHRNA7PFKFB3TYRPTPN1
SCHEMBL3483606 0.91 CHRNA7 (0.65) PKMCHRNA7PFKFB3TYRPTPN1
SCHEMBL3483621 0.91 PKM (0.53) PKMCHRNA7PFKFB3TYRPTPN1
SCHEMBL3483605 0.91 CHRNA7 (0.65) PKMCHRNA7PFKFB3TYRPTPN1
SCHEMBL3483735 0.90 CHRNA7 (0.50) CHRNA7TYRPTPN1KMT2AMAPT
SCHEMBL3484177 0.90 P4HB (0.53) CHRNA7TYRKMT2AMAPTMAPK1
SCHEMBL3484178 0.90 P4HB (0.53) CHRNA7TYRKMT2AMAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP claimed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US claimed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP claimed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US claimed
EP-2601943-B1 Anti-cancer composition containing chalcone compounds SEOUL NAT UNIV IND FOUNDATION (KR) 2015-07-22 EP disclosed
US-9072698-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2015-07-07 US disclosed
US-9057725-B2 Composition for diagnosing, treating, and preventing liver disease SNU R&DB FOUNDATION (KR) 2015-06-16 US disclosed
US-20130178533-A1 COMPOSITION FOR DIAGNOSING, TREATING, AND PREVENTING LIVER DISEASE SNU R&DB FOUNDATION (KR) 2013-07-11 US disclosed
EP-2601943-A1 Anti-cancer composition containing chalcone compounds Seoul National University Industry Foundation (KR) 2013-06-12 EP disclosed
US-8445722-B2 Method for screening anti-cancer compounds inhibiting function of TM4SF5 and anti-cancer composition containing chalcone compounds INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY (KR) 2013-05-21 US disclosed
EP-2099440-B1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 SEOUL NAT UNIV IND FOUNDATION (KR) 2013-02-27 EP disclosed
US-20120282619-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY 2012-11-08 US disclosed
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS SEOUL NATIONAL UNIVERSITY INDUSTRY FOUNDATION (KR) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100068730-A1 METHOD FOR SCREENING ANTI-CANCER COMPOUNDS INHIBITING FUNCTION OF TM4SF5 AND ANTI-CANCER COMPOSITION CONTAINING CHALCONE COMPOUNDS TM9SF4, TM9SF2, TM9SF3 PKM 3835/4885CHRNA7 4573/4885PFKFB3 4104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.